EHA 2019 | Imetelstat provides durable transfusion independence in lower risk MDS group

Pierre Fenaux

In this press briefing, recorded at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands, Pierre Fenaux of St Louis Hospital, Paris, France, presents data on the use of imetelstat in lower risk myelodysplastic syndrome (MDS) patients. Treatment with imetelstat, a telomerase inhibitor, was shown to provide durable transfusion independence in heavily transfused non-del(5q) lower risk MDS that is relapsed/refractory to erythropoietic stimulating agents.

Share this video  
Similar topics